Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Glioblastoma Foundation Inc
Deal Size : Undisclosed
Deal Type : Agreement
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Details : Under the terms of the agreement, Basilea sells and transfers all rights to BAL101553 (lisavanbulin) to the Glioblastoma Foundation. It is currently being evaluated for the treatment of neoplasms.
Product Name : BAL101553
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 20, 2024
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Glioblastoma Foundation Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Basilea Gets U.S. FDA Orphan Drug Designation for Lisavanbulin
Details : In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.
Product Name : BAL101553
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable